概述
-
货号
DHJ41099
-
描述
Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE) , suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer.
-
种属反应性
Human -
克隆类型
Monoclonal -
靶标
LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4 -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>90% as determined by SEC. -
纯化方式
Purified by Ion Exchange Chromatography. -
克隆号
Enfortumab vedotin-ejfv
-
应用
Research Grade Biosimilar -
状态
Liquid -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
Padcev, ASG-22ME
图片
参考文献
评价
